The following pipeline consists of programs and platform that are of strategic importance for Elpiscience to deliver the next generation of cancer immunotherapies.
-
AssetTargetIndicationsDiscoveryPreclinicalPh1Ph2Ph3Partner
-
ES104VEGF/DLL4
- BTC, CRC, OC
-
ES102OX40
- NSCLC, HNSCC
-
ES014CD39/TGF-β
- Solid Tumors
-
ES009LILRB2
- Solid Tumors
-
ES002CD39
- Solid Tumors
-
ES004SIRPα
- Solid Tumors
-
ES019 (BiME®)SIRPα/PD-L1
- Solid Tumors
-
Other BiME® ProgramsSIRPα/TAA
- Solid Tumors
-
View MoreES104TargetVEGF/DLL4
- Discovery Preclinical Ph1 Ph2 Ph3
-
+chemo
-
View MoreES102TargetOX40
- Discovery Preclinical Ph1 Ph2 Ph3
-
+PD-1
-
View MoreES014TargetCD39/TGF-β
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/+chemo/+IOs
-
View MoreES009TargetLILRB2
- Discovery Preclinical Ph1 Ph2 Ph3
-
+PD-1
-
View MoreES002TargetCD39
- Discovery Preclinical Ph1 Ph2 Ph3
-
Combo
-
View MoreES004TargetSIRPα
- Discovery Preclinical Ph1 Ph2 Ph3
-
Combo
-
View MoreES019 (BiME®)TargetSIRPα/PD-L1
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/Combo
-
View MoreOther BiME® ProgramsTargetSIRPα/TAA
- Discovery Preclinical Ph1 Ph2 Ph3
-
Monotherapy/Combo
